

IN THE SPECIFICATION:

At the end of the specification, after paragraph [106], please insert the following:

Abstract

[0107] The present invention relates to a novel antifungal target, tRNA ligase (TRL1), screening methods for TRL1 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of an individual susceptible to or suffering from an anti-fungal infection. In particular the compounds find use in the treatment of topical or mucosal (e.g. thrush and vaginal candidiasis) fungal infections, e.g. caused by fungus of the *Candida* species, and for systemic infections, e.g. caused by fungi of *Candida* and *Aspergillus* species, such as but not limited to *C. albicans*, *Aspergillus flavus* or *Aspergillus fumigatus*.